Overview

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with temozolomide may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib when given together with temozolomide in treating patients with brain tumors or other solid tumors that have not responded to treatment.

Phase:

Phase 1

Details

Lead Sponsor:

City of Hope Medical Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Bortezomib
Dacarbazine
Temozolomide